Payment overview · 2025
General Payments
$3,734.50
99 reported records · 11 companies
Healthcare provider profile · identity verified
David Magier, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT NECK, NY · NPI 1285634196
Verified facts
What the public records show
CMS Open Payments records show David Magier, M.D. received $3,734.50 in general payments during 2025 across 99 reported records.
Madrigal Pharmaceuticals accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Voquezna, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Voquezna by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PLENVU as an associated drug or biological on 1016 records involving 359 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Plenvu by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $1,318.34 | 35.3% | 22 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $515.31 | 13.8% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $466.56 | 12.5% | 31 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $319.22 | 8.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $267.03 | 7.2% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $230.37 | 6.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $195.79 | 5.2% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $155.97 | 4.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.41 | 4.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.85 | 1.8% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $44.65 | 1.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,734.50 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $1,318.34 | 22 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $466.56 | 31 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $319.22 | 5 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $246.48 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $230.37 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $195.79 | 10 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $155.97 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $154.41 | 4 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $124.62 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $124.62 | 1 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.55 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.55 | 4 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $5.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 88 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
88 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | PLENVU open payments reported associated product |
CMS Open Payments — General Payments 1016 supporting records · 359 recipient NPIs · example record 1231776646 |
Plenvu · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 142 |
| Famotidine | Famotidine | 425 | 141 |
| Atorvastatin Calcium | Atorvastatin Calcium | 423 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 104 |
| Losartan Potassium | Losartan Potassium | 348 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 51 |
| Omeprazole | Omeprazole | 203 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 50 |
| Dexlansoprazole Dr | Dexlansoprazole | 144 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 36 |
| Alprazolam | Alprazolam | 143 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 38 |
| Mounjaro | Tirzepatide | 133 | 28 |
| Metformin Hcl | Metformin Hcl | 132 | 35 |
| Repatha Sureclick | Evolocumab | 129 | 18 |
| Simvastatin | Simvastatin | 122 | 36 |
| Furosemide | Furosemide | 113 | 33 |
| Prednisone | Prednisone | 107 | 74 |
| Metformin Hcl Er | Metformin Hcl | 104 | 25 |
| Azithromycin | Azithromycin | 101 | 78 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 100 | 98 |
| Synthroid | Levothyroxine Sodium | 99 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 27 |
| Linzess | Linaclotide | 88 | 26 |
| Allopurinol | Allopurinol | 87 | 18 |
| Gabapentin | Gabapentin | 84 | 25 |
| Eliquis | Apixaban | 80 | 18 |
| Hydrocortisone | Hydrocortisone | 77 | 34 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 31 |
| Mirtazapine | Mirtazapine | 72 | 24 |
| Meloxicam | Meloxicam | 68 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 23 |
| Clenpiq | Sod Picosulf/Mag Ox/Citric Ac | 62 | 58 |
| Ozempic | Semaglutide | 61 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 48 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 55 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 13 |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 14 |
| Atenolol | Atenolol | 48 | 12 |
| Jardiance | Empagliflozin | 48 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Farxiga | Dapagliflozin Propanediol | 45 | 12 |
| Klor-Con M20 | Potassium Chloride | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Lisinopril | Lisinopril | 38 | 11 |
| Potassium Chloride | Potassium Chloride | 38 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 18 |
| Trulance | Plecanatide | 36 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 23 |
| Plenvu | Peg3350/Sod Sul/Nacl/Kcl/Asb/C | 33 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 12 |
| Myrbetriq | Mirabegron | 28 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Valsartan | Valsartan | 28 | 11 |
| Glipizide | Glipizide | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 25 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 23 | suppressed |
| Mesalamine | Mesalamine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 11 |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Voquezna | Vonoprazan Fumarate | 19 | suppressed |
| Carafate | Sucralfate | 18 | suppressed |
| Mesalamine Er | Mesalamine | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Gattex | Teduglutide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,734.50 · 99 records | Madrigal Pharmaceuticals | CREON, DUPIXENT, IBSRELA, IQIRVO, LINZESS, Livdelzi, REZDIFFRA, SKYRIZI, TREMFYA, VELSIPITY, VIBERZI, VOQUEZNA, Vemlidy, Wegovy, XELJANZ, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error